Dr. Reddy's Laboratories Limited (FRA:RDDA)
Germany · Delayed Price · Currency is EUR 10.90
0.00 (0.00%)
At close: Jan 30, 2026
Dr. Reddy's Laboratories Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Net Income | 56,587 | 56,544 | 55,684 | 45,067 | 23,568 | 17,238 |
Depreciation & Amortization | 19,583 | 17,058 | 14,841 | 12,636 | 11,824 | 12,796 |
Loss (Gain) From Sale of Assets | -1,514 | -1,522 | -900 | 208 | -1,119 | 42 |
Asset Writedown & Restructuring Costs | 1,701 | 1,693 | 3 | 699 | 7,562 | 8,588 |
Loss (Gain) From Sale of Investments | -2,566 | -3,554 | -3,149 | -876 | -277 | -557 |
Loss (Gain) on Equity Investments | -143 | -217 | -147 | -370 | -703 | -480 |
Stock-Based Compensation | 345 | 424 | 407 | 397 | 592 | 584 |
Provision & Write-off of Bad Debts | 698 | 161 | 275 | 205 | 55 | 230 |
Other Operating Activities | 6,704 | 5,830 | -1,399 | 8,764 | 5,104 | 7,980 |
Change in Accounts Receivable | -8,283 | -10,283 | -8,054 | -5,752 | -17,012 | 2,081 |
Change in Inventory | -10,707 | -12,753 | -18,445 | -2,654 | -9,912 | -12,402 |
Change in Accounts Payable | 4,788 | 340 | 3,460 | 23 | 4,412 | 2,861 |
Change in Other Net Operating Assets | -4,087 | -7,293 | 2,857 | 528 | 4,014 | -3,258 |
Operating Cash Flow | 63,106 | 46,428 | 45,433 | 58,875 | 28,108 | 35,703 |
Operating Cash Flow Growth | 75.53% | 2.19% | -22.83% | 109.46% | -21.27% | 19.64% |
Capital Expenditures | -26,450 | -27,504 | -16,403 | -11,323 | -14,660 | -9,741 |
Sale of Property, Plant & Equipment | 142 | 512 | 1,064 | 82 | 370 | 85 |
Cash Acquisitions | -1,655 | -53,096 | - | - | -326 | -15,514 |
Sale (Purchase) of Intangibles | -11,704 | -6,162 | -11,011 | -7,543 | -1,443 | -2,820 |
Investment in Securities | -14,843 | 24,801 | -15,716 | -23,366 | -11,201 | 4,110 |
Other Investing Activities | 2,183 | 3,372 | 1,783 | 777 | 873 | 1,220 |
Investing Cash Flow | -52,327 | -58,077 | -40,283 | -41,373 | -26,387 | -22,660 |
Short-Term Debt Issued | - | 24,490 | 5,493 | - | 3,520 | 6,791 |
Long-Term Debt Issued | - | - | 3,800 | - | - | 3,800 |
Total Debt Issued | 6,753 | 24,490 | 9,293 | - | 3,520 | 10,591 |
Short-Term Debt Repaid | - | - | - | -19,382 | - | - |
Long-Term Debt Repaid | - | -1,294 | -4,947 | -1,015 | -785 | -4,497 |
Total Debt Repaid | -1,106 | -1,294 | -4,947 | -20,397 | -785 | -4,497 |
Net Debt Issued (Repaid) | 5,647 | 23,196 | 4,346 | -20,397 | 2,735 | 6,094 |
Issuance of Common Stock | 329 | 193 | 805 | 368 | 334 | 269 |
Repurchase of Common Stock | -1,389 | -1,389 | - | - | - | -1,193 |
Common Dividends Paid | -6,659 | -6,662 | -6,648 | -4,979 | -4,146 | -4,147 |
Other Financing Activities | -4,047 | 3,573 | -2,266 | -1,853 | -1,345 | -1,321 |
Financing Cash Flow | -6,119 | 18,911 | -3,763 | -26,861 | -2,422 | -298 |
Foreign Exchange Rate Adjustments | 965 | 224 | -59 | 286 | 733 | 113 |
Net Cash Flow | 5,625 | 7,486 | 1,328 | -9,073 | 32 | 12,858 |
Free Cash Flow | 36,656 | 18,924 | 29,030 | 47,552 | 13,448 | 25,962 |
Free Cash Flow Growth | 237.35% | -34.81% | -38.95% | 253.60% | -48.20% | 3.87% |
Free Cash Flow Margin | 10.60% | 5.81% | 10.40% | 19.34% | 6.27% | 13.68% |
Free Cash Flow Per Share | 44.01 | 22.69 | 34.83 | 57.16 | 16.17 | 31.22 |
Cash Interest Paid | 4,047 | 3,483 | 2,266 | 1,853 | 1,345 | 1,321 |
Cash Income Tax Paid | 16,495 | 19,993 | 20,047 | 10,714 | 7,437 | 5,716 |
Levered Free Cash Flow | 13,469 | 11,920 | 12,406 | 29,677 | 1,031 | 19,259 |
Unlevered Free Cash Flow | 15,555 | 13,688 | 13,476 | 30,569 | 1,629 | 19,865 |
Change in Working Capital | -18,289 | -29,989 | -20,182 | -7,855 | -18,498 | -10,718 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.